The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
By S. Lakhani, M. J. van de Vijver, J. Jacquemier, T. Anderson, P. Osin, L. McGuffog, D. Easton. Journal of Clinical Oncology, 2002
878 citations recorded by the source corpus.
Subfields: Cancer Research, Epidemiology, Genetics
View Paper: https://www.semanticscholar.org/paper/02ec5af1ee6a6145f234b9a89a8ce9cd1c1cc25c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- J. Reis-Filho
- J. Peto
- Michael R. Stratton
- K. J. Chavez
- M. J. van de Vijver
- S. Garimella
- S. Lipkowitz
In Genetics
Citations in the corpus
- An overview of triple-negative breast cancer (2016, background): “Germline mutations in the BRCA1 breast and ovarian cancer susceptibility gene have been associated with TNBC, with 60–80 % of breast tumors from BRCA1 mutation carriers displaying a TNBC phenotype [44, 45].”
- Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype (2005, background): “ER positive 6% (12) 2% (4) 1% (2) 11% (30) 5% (6) ER negative 22% (28) 16% (18) 28% (36) 33% (42) 47% (40) Grade 1 6% ( 3 ) 0% (0) 0% (0) 9% (7) 0% (0) 2 7% (7) 0% (0) 2% (2) 13% (15) 11% (6) 3 16% (30) 12% (22) 17% (36) 24% (52) 34% (40)”
- Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas (2007, background): “Specific subgroups of triple-negative tumors may be formed by medullary and atypical medullary cancers [12,37-39].”
- Triple-negative breast cancer--current status and future directions. (2009, background): “Conversely, a significant association of BRCA1-mutated cases with typical molecular features of TNBC, such as EGFR/CK 5/6 expression, ER/HER-2 negativity, and p53 mutations [82, 94] has been reported.”
- Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer (2010, background): “Tumors that are BRCA1 deficient are most commonly basal-like TNBC [53, 54].”
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality (2010, neutral): “The potentially larger risk reduction associated with risk-reducing salpingo-oophorectomy in BRCA2 compared with BRCA1 mutation carriers is of interest given the high proportion of ER-positive breast tumors in BRCA2 mutation carriers compared with BRCA1 mutation carriers.(31) Additional research is ”